Frontiers in Immunology (Jul 2022)

A 9-LncRNA Signature for Predicting Prognosis and Immune Response in Diffuse Large B-Cell Lymphoma

  • Xiaoxuan Wang,
  • Yaxiao Lu,
  • Ziyi Liu,
  • Yidan Zhang,
  • You He,
  • Cong Sun,
  • Lanfang Li,
  • Qiongli Zhai,
  • Bin Meng,
  • Xiubao Ren,
  • Xudong Wu,
  • Xudong Wu,
  • Huilai Zhang,
  • Xianhuo Wang

DOI
https://doi.org/10.3389/fimmu.2022.813031
Journal volume & issue
Vol. 13

Abstract

Read online

Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous disease that requires personalized clinical treatment. To assign patients into different risk categories, cytogenetic abnormalities and genetic mutations have been widely applied to the prognostic stratification of DLBCL. Increasing evidence has demonstrated that deregulated epigenetic modifications and long noncoding RNAs (lncRNAs) contribute to the initiation and progression of DLBCL. However, specific lncRNAs that affect epigenetic regulation and their value in predicting prognosis and therapy response remain uncertain. Here, 2,025 epigenetic-related genes were selected, and 9 lncRNAs (PRKCQ-AS1, C22orf34, HCP5, AC007389.3, APTR, SNHG19, ELFN1-AS1, LINC00487, and LINC00877) were tested and validated to establish an lncRNA-regulating epigenetic event signature (ELncSig). ELncSig, which was established based on independent lymphoma datasets, could distinguish different survival outcomes. Functional characterization of ELncSig showed that it could be an indicator of the immune microenvironment and is correlated with distinctive mutational characteristics. Univariate and multivariate analyses showed that ELncSig was independent of traditional prognostic factors. The novel immune-related ELncSig exhibits promising clinical prognostic value for DLBCL.

Keywords